

## Medical Personal History

### Allergies & Intolerances

#### Intolerance - Drug

Type	Propensity to adverse reactions to drug
Description	Intolerance to ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS / eosinophilia and systemic symptoms
Criticality	Medium Risk
Code	ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
Clinical Status	Active
Recorded Date	11/20/2010
Onset	10/20/2010
Last Occurance	10/03/2022
End Date	-
Note	The criticality is medium since it happened only once and severity of the reaction might be high.

Reaction 1	Manifestation	Drug reaction with eosinophilia and systemic symptoms
	Description	Challenge Protocol. Severe reaction to subcutaneous peanut extract. Epinephrine administered
	Onset	10/20/2010
	Severity	Life threatening severity
	Exposure Route	Gastro-intestinal stoma

High Risk No Drug Allergy

Type	Food allergy
Description	Allergy to peanuts due to anaphylaxis
Criticality	High Risk
Code	Peanut
Clinical Status	Active
Recorded Date	11/20/2010
Onset	10/20/2010
Last Occurance	10/03/2022
End Date	-
Note	The criticality is high because of the observed anaphylactic reaction when challenged with peanut extract.

Reaction 1	Manifestation	Anaphylaxis
	Description	Challenge Protocol. Severe reaction to subcutaneous peanut extract. Epinephrine administered
	Onset	10/20/2010
	Severity	Life threatening severity
	Exposure Route	Gastro-intestinal stoma route

Reaction 2	Manifestation	Anaphylaxis
	Description	Challenge Protocol. Severe reaction to subcutaneous peanut extract. Epinephrine administered
	Onset	10/20/2010
	Severity	Life threatening severity
	Exposure Route	Gastro-intestinal stoma route

### Medical Problems and procedures

Current Problems	Problem / Diagnosis Description	Challenge Protocol. Severe reaction to subcutaneous peanut extract. Epinephrine administered
	Onset Date	12/11/2021
Resolved, Closed or Inactive Problems	Problem Description	Hemorrhage of thyriod
	Onset date	10/11/2021
	End Date	12/11/2021
	Dianosis Age	25
Procedures	Problem Description	Exploration of parathyroid with mediastinal exploration by sternal split approach
	Body Side	Parathyroid gland
	Procedure Date	15/12/2021
Functional Status	Description	Needs help in bathing more than one part of the body getting out of the tub or shower. Requires total bathing.
	Onset date	12/11/2021

### Medical Devices & Implants

Device and Implant Description	Description goes here
Onset Date	12/11/2021

### Medication Summary

Brand Name	ATACAND PLUS TABLET 16MG/12. 5MG
Active Ingredient Lists	Candesartan and diuretics
Active Ingredient Code	C09DA06
Strength	16MG/12.5MG
Pharmaceutical Dose Form	Tablet
Dosage Regimen	1 tablet every 24h, for 10 days
Number of units per intake	1
Frequency of intake	Every 1 day(s)
Duration of treatment	10 day(s)
Route of Administration	Oral use
Date of Onset of Treatment	44643
Additional Instructions	12/11/2021

### Laboratory Examinations

Empty	
-------	--

### Gynaecological History

#### Pregnancy History

Current Pregnancy Status	Date of Observation	12/11/2021
	Status	Not Pregnant
Expected Date of Delivery	-	

### Social History

Consumption of Alcohol	Date Start	12/11/1992
	Date End	12/11/2021
	Alcohol Status	Lifetime drinker of alcohol
	Alcohol Intake (unit per day)	20cl per day
	Alcohol Type	Distilled spirits
Tobacco Use	Date Start	12/11/1992
	Date End	12/11/2021
	Tobacco Status	Current smoker
	Tobacco Type	Electronic cigarette user
	Pack Years	25 Years
Drug Use	Date Start	12/11/1992
	Date End	12/11/2021
	Drug Use Status	Has misused drugs
	Drug or Medication Type	Methylenedioxyamphetamine
	Daily Dosage	2 grams per day
Sleep	Route of Administration	Route of administration not applicable
	Date Start	12/11/1992
	Date End	12/11/2021
Exccercise	Finding Related to Sleep	Decreased need for sleep
	Exercise Activity	Trail walk
	Frequency Per Week	1
	Exercise Duration	120 minutes
	Exercise Intensity	Moderate

### Vaccinations

Disease or agent targeted	Diphtheria due to Corynebacterium diphtheriae
Vaccine/prophyla xis	Diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae b vaccine
Vaccine medicinal product	-
Marketing Autorisation Holder	-
Number in a series of vaccinations / doses	2nd dosage
Batch/lot number	3
Date of vaccination	12/11/2021
Health Professional identification	Maria Eracleous
Administering centre	Ammochostos General Hospital
Health Professional identification	Health Professional identification
Country of vaccination	Cyprus
Next vaccination date	12/11/2022

### Epidemiological History

Travel History	Destination	Germany
	Date of Departure	12/11/2021
	Date of Arrival	13/11/2021

### Discharge Summary

Resolved, Closed or Inactive Problems	Problem Description	Hemorrhage of thyriod
	Onset date	10/11/2021
	End Date	12/11/2021
	Dianosis Age	25
Procedures	Problem Description	Exploration of parathyroid with mediastinal exploration by sternal split approach
	Body Side	Parathyroid gland
	Procedure Date	15/12/2021